Exploring the utility of high-resolution MS with post-acquisition data mining for simultaneous exogenous and endogenous metabolite profiling

Bioanalysis

Volumn 5, Issue 10, 2013, Pages 1211-1228

  Barbara, Joanna E ^a   Buckley, David B ^a   Horrigan, Mark J ^a  

^a XenoTech LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; DRUG METABOLITE; GLUTATHIONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CONTROLLED STUDY; DATA COLLECTION METHOD; DATA MINING; DATA STORAGE DEVICE; DRUG DETERMINATION; DRUG STRUCTURE; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; LIPID ANALYSIS; LIVER MICROSOME; MALE; MOLECULAR MODEL; PEPTIDE ANALYSIS; QUANTITATIVE ANALYSIS; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

BIOLOGICAL MARKERS; DATA MINING; GLUTATHIONE; HUMANS; LIPIDS; MASS SPECTROMETRY; METABOLOMICS; MICROSOMES, LIVER; PYRIMIDINES; THIAZOLES;

EID: 84878488570     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.102     Document Type: Article

References (35)

1. Fung EN, Xia YQ, Aubry AF et al. Full scan high resolution accurate mass spectrometry (HRMS) in regulated bioanalysis: LC-HRMS for the quantitation of prednisone and prednisolone in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879(27), 2919-2927 (2011).
2. Meyer MR, Maurer HH. Current applications of high-resolution mass spectrometry in drug metabolism studies. Anal. Bioanal. Chem. 403(5), 1221-1231 (2012).
3. Zhu M, Zhang H, Humphreys WG. Drug metabolite profling and identifcation by high-resolution mass spectrometry. J. Biol. Chem. 286(29), 25419-25425 (2011).
4. Josephs JL. HRMS: current usage, future directions and the promise of integration with unifed data streams suited to post-acquisition mining. Bioanalysis 4(5), 471-476 (2012).
5. Castro-Perez J, Plumb R, Granger JH et al. Increasing throughput and information content for in vitro drug metabolism experiments using ultra-performance liquid chromatography coupled to a quadrupole time-of-fight mass spectrometer. Rapid Commun. Mass Spectrom. 19(6), 843-848 (2005).
6. E with in silico data mining is an information-rich approach to reactive metabolite screening. Rapid Commun. Mass Spectrom. 25(20), 3029-3040 (2011).
7. Wrona M, Mauriala T, Bateman KP et al. 'All-in-one' analysis for metabolite identifcation using liquid chromatography/hybrid quadrupole time-of-fight mass spectrometry with collision energy switching. Rapid Commun. Mass Spectrom. 19 (18), 2597-2602 (2005).
8. Tiller PR, Yu S, Castro-Perez J et al. High-throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time-of-fight system as a 'frst-line' approach for metabolite identifcation studies. Rapid Commun. Mass Spectrom. 22(7), 1053-1061 (2008).
9. Tian Y, He J, Zhang R et al. Integrated rapid resolution liquid chromatography-tandem mass spectrometric approach for screening and identifcation of metabolites of the potential anticancer agent 3, 6, 7-trimethoxyphenanthroindolizidine in rat urine. Anal. Chim. Acta 731, 60-67 (2012).
10. Du F, Liu T, Liu T et al. Metabolite identifcation of triptolide by data-dependent accurate mass spectrometric analysis in combination with online hydrogen/deuterium exchange and multiple data mining techniques. Rapid Commun. Mass Spectrom. 25(20), 3167-3177 (2011).
11. Ma S, Chowdhury SK. Application of LC-high-resolution MS with 'intelligent' data mining tools for screening reactive drug metabolites. Bioanalysis 4(5), 501-510 (2012).
12. Emary WB, Zhang NR. Emerging applications for high-resolution MS in discovery bioanalysis. Bioanalysis 3(22), 2485-2489 (2011).
13. Smith CA, Want EJ, O'Maille G et al. XCMS: processing mass spectrometry data for metabolite profling using nonlinear peak alignment, matching, and identifcation. Anal. Chem. 78(3), 779-787 (2006).
14. Castro-Perez J, Kamphorst J, DeGroot J et al. Comprehensive LC-MS E lipidomic analysis using a shotgun approach and its application to biomarker detection and identifcation in osteoarthritis patients. J. Proteome. Res. 9(5), 2377-2389 (2010).
15. Sugimoto M, Kawakami M, Robert M et al. Bioinformatics tools for mass spectroscopy-based metabolomic data processing and analysis. Curr. Bioinform. 7(1), 96-108 (2012).
16. Ramanathan R, Jemal M, Ramagiri S et al. It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. J. Mass Spectrom. 46 (6), 595-601 (2011).
17. Ramanathan R, Korfmacher W. The emergence of high-resolution MS as the premier analytical tool in the pharmaceutical bioanalysis arena. Bioanalysis 4(5), 467-469 (2012).
18. Nagele E, Fandino AS. Simultaneous determination of metabolic stability and identifcation of buspirone metabolites using multiple column fast liquid chromatography time-of-fight mass spectrometry. J. Chromatogr. A 1156(1-2), 196-200 (2007).
19. Bateman KP, Kellmann M, Muenster H et al. Quantitative-qualitative data acquisition using a benchtop Orbitrap mass spectrometer. J. Am. Soc. Mass Spectrom. 20 (8), 1441-1450 (2009).
20. 14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys. Drug Metab. Dispos. 36(7), 1341-1356 (2008).
21. Duckett DR, Cameron MD. Metabolism considerations for kinase inhibitors in cancer treatment. Expert. Opin. Drug Metab. Toxicol. 6 (10), 1175-1193 (2010).
22. E with mass defect fltering for in vitro and in vivo metabolite identifcation. Rapid Commun. Mass Spectrom. 21(9), 1485-1496 (2007).
23. Rousu T, Pelkonen O, Tolonen A. Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-fight mass spectrometry. Rapid Commun. Mass Spectrom. 23(6), 843-855 (2009).
24. Liang Y, Wang G, Xie L et al. Recent development in liquid chromatography/mass spectrometry and emerging technologies for metabolite identifcation. Curr. Drug Metab. 12(4), 329-344 (2011).
25. Ma S, Chowdhury SK. Analytical strategies for assessment of human metabolites in preclinical safety testing. Anal. Chem. 83(13), 5028-5036 (2011)
26. Gonzalez E, Van LS, Conde-Vancells J et al. Serum UPLC-MS/MS metabolic profling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity. Metabolomics 8(6), 997-1011 (2012).
27. Hu C, van der Heijden R, Wang M et al. Analytical strategies in lipidomics and applications in disease biomarker discovery. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(26), 2836-2846 (2009).
28. Mortishire-Smith RJ, Castro-Perez JM, Yu K et al. Generic dealkylation: a tool for increasing the hit-rate of metabolite rationalization, and automatic customization of mass defect flters. Rapid Commun. Mass Spectrom. 23(7), 939-948 (2009).
29. Wishart DS, Jewison T, Guo AC et al. HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res. 41(Database issue), D801-D807 (2013).
30. Christopher LJ, Cui D, Wu C et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 36(7), 1357-1364 (2008).
31. Wang L, Christopher LJ, Cui D et al. Identifcation of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab. Dispos. 36(9), 1828-1839 (2008).
32. Castro-Perez JM. Applications of quadrupole time-of-fight mass spectrometry in reactive metabolite screening. In: Mass Spectrometry in Drug Metabolism and Pharmacokinetics. Ramanathan R (Ed.). John Wiley and Sons, Inc., Hoboken, NJ, USA, 159-190 (2009).
33. Li X, He Y, Ruiz CH et al. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos. 37(6), 1242-1250 (2009).
34. Li F, Qui X, Chen H et al. Lipid profling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun. Mass Spectrom. 27(1), 24-34 (2013).
35. Serrels A, Macpherson IR, Evans TR et al. Identifcation of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol. Cancer Ther. 5(12), 3014-3022 (2006).